701 Pennsylvania Ave., N.W.
Washington, DC 20004
Aaron L. Josephson
– Washington DC
Aaron advises clients on health care policy issues related to medical devices and pharmaceuticals.
Prior to joining ML Strategies, Aaron spent 10 years with the US Food and Drug Administration, most recently as a senior policy advisor in the Center for Devices and Radiological Health where he led legislative policy development activities related to all aspects of medical device regulation and oversight. He also apprised members of Congress and their staffs about FDA policies and programs and advised multiple FDA Commissioners and other senior officials on strategy and content for meetings with Congress, industry representatives, and other stakeholders. In addition to negotiating the reauthorization of the medical device user fee program (MDUFA), Aaron led FDA’s implementation of key provisions of the 21st Century Cures Act and the FDA Reauthorization Act.
Earlier, Aaron was a budget analyst in the FDA’s Center for Drug Evaluation and Research, where he developed the center’s annual budget and provided information to the Congressional Budget Office (CBO) and congressional authorizers. He began his FDA career in the Center for Biologics Evaluation and Research as an information management specialist responsible for data analyses to support FDA policies and programs.
During his tenure with the FDA, Aaron won numerous agency awards, including the Lireka P. Joseph Award for Excellence in Public Health Communication or Education. He also received special recognition from multiple FDA Commissioners, including a June 2017 special citation for outstanding and sustained performance in the negotiation and reauthorization of MDUFA IV and an August 2016 award for contributions to the 21st Century Cures Act.
Aaron earned a master’s certificate in project management from the George Washington University School of Business and is certified by the American Society for Quality as a quality improvement associate.
M.S., Regulatory Science, Johns Hopkins University
B.A., Political Science, University of Virginia
Quoted in Device Expert: FDA De Novo Rule Provides Clarity For Industry, Inside Health Policy (12.04.2018)
Quoted in Drug Lawyers: FDA’s Complete Response Letters Are Anything But, Inside Health Policy (11.08.2018)
Quoted in Medical Device Expert: FDA Report Responds To Enforcement Criticism, Inside Health Policy (11.29.2016)